PROGEN

Executive Summary

PROGEN, founded in 1983 and headquartered in Heidelberg, Germany, is a specialized biotechnology company delivering high-quality analytical tools and antibodies for gene therapy, with a focus on adeno-associated virus (AAV) analytics. ISO 13485 certified, its portfolio includes ELISAs, antibodies, standards, and density gradient media, essential for the development and quality control of safe and affordable gene therapies. Operating globally through its German base and US subsidiary, PROGEN serves a rapidly growing market as gene therapy advances toward commercialization. The company's long track record and niche expertise position it as a key enabler in the AAV analytics space, though being private limits visibility into financial performance.

Upcoming Catalysts (preview)

• Q4 2026Launch of next-generation AAV serotype ELISA kits70% success
• TBDStrategic partnership with a leading gene therapy developer60% success
• Q2 2027FDA clearance or CE marking for a diagnostic assay using PROGEN reagents40% success